Moreover, with or without supplementation of IL-1α, tumor-induced osteoclastogenesis was sensitive to CBD and resistant to denosumab, whereas RANKL-induced osteoclastogenesis was resistant to CBD and sensitive to denosumab. Here, IL1A is linked to neoplasm.